Renal retransplantation: a retrospective monocentric study

Area of Science:

• Nephrology
• Transplantation Immunology

Background:

• Renal retransplantation is common, accounting for 10-20% of annual procedures.
• Retransplanted patients face significantly higher immunological risks than first-time recipients.
• Data on retransplantation outcomes are limited, necessitating further clinical investigation.

Purpose of the Study:

• To retrospectively analyze outcomes in patients undergoing second or third kidney retransplantations.
• To compare the efficacy and safety of thymoglobulin versus basiliximab induction therapy in renal retransplantation.
• To identify factors influencing graft survival and patient outcomes in this high-risk population.

Main Methods:

• Retrospective analysis of 50 recipients undergoing second or third renal transplantations.
• Immunosuppression included corticosteroids, mycophenolate mofetil (MMF), and tacrolimus.
• Induction therapy compared thymoglobulin (n=27) versus basiliximab (n=22).

Main Results:

• Acute rejection rates were higher with thymoglobulin (44.4%) than basiliximab (31.8%).
• Basiliximab recipients showed better renal function at 1 year (serum creatinine 134.3 vs 199.6 µmol/L).
• Allograft failure was slightly higher in the basiliximab group (18.1% vs 14.8%), and severe vascular rejections were noted.

Conclusions:

• Renal retransplantation presents substantial immunological and rejection risks.
• Thymoglobulin induction may be preferable for reducing severe vascular rejection and preventing allograft failure.
• While basiliximab showed better early renal function, thymoglobulin might offer superior long-term graft survival in retransplanted patients.